drugset / Trial / NCT05278832

A Study of QLS31905 in Patients With Advanced Solid Tumors

NCT05278832

Phase 1 Unknown 104 enrolled Qilu Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a multi-center, open-label design to evaluate the safety and tolerance of QLS31905 in patients with advanced solid tumors, together with an assessment of pharmacokinetic characteristics and efficacy.

Timeline

Start
2021-10-25
Primary completion
2022-12-31
Completion
2023-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject QLS31905 Unknown

Indications